Loading...
•
Sep 30, 2020
PMV Pharma Q3 2020 Earnings Report
PMV Pharma reported financial results for Q3 2020 and provided corporate highlights.
Key Takeaways
PMV Pharma reported a net loss of $8.8 million for the quarter ended September 30, 2020. The company ended the quarter with $373.1 million in cash, cash equivalents, and marketable securities. The FDA cleared the IND application for lead product candidate PC14586.
Received IND clearance from the FDA to initiate a Phase 1/2 study of PC14586 in patients with advanced solid tumors that have a p53 Y220C mutation.
The U.S. FDA granted PMV Pharma Fast Track designation to PC14586 for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation.
Expanded PMV Pharma’s management team and Board of Directors.
Successfully completed an IPO at a public offering price of $18 per share, with gross proceeds totaling approximately $243.5 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...